JP5513375B2 - 癌の検出方法および検出用キット、ならびに癌治療剤 - Google Patents

癌の検出方法および検出用キット、ならびに癌治療剤 Download PDF

Info

Publication number
JP5513375B2
JP5513375B2 JP2010511025A JP2010511025A JP5513375B2 JP 5513375 B2 JP5513375 B2 JP 5513375B2 JP 2010511025 A JP2010511025 A JP 2010511025A JP 2010511025 A JP2010511025 A JP 2010511025A JP 5513375 B2 JP5513375 B2 JP 5513375B2
Authority
JP
Japan
Prior art keywords
mir
gene
cancer
cpg
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010511025A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2009136501A1 (ja
Inventor
拓 鈴木
実 豊田
浩三 今井
恭久 篠村
隆至 時野
Original Assignee
北海道公立大学法人 札幌医科大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北海道公立大学法人 札幌医科大学 filed Critical 北海道公立大学法人 札幌医科大学
Priority to JP2010511025A priority Critical patent/JP5513375B2/ja
Publication of JPWO2009136501A1 publication Critical patent/JPWO2009136501A1/ja
Application granted granted Critical
Publication of JP5513375B2 publication Critical patent/JP5513375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2010511025A 2008-05-07 2009-05-07 癌の検出方法および検出用キット、ならびに癌治療剤 Active JP5513375B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010511025A JP5513375B2 (ja) 2008-05-07 2009-05-07 癌の検出方法および検出用キット、ならびに癌治療剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008121671 2008-05-07
JP2008121671 2008-05-07
PCT/JP2009/002007 WO2009136501A1 (fr) 2008-05-07 2009-05-07 Procédé et trousse de détection du cancer, et agent thérapeutique contre le cancer
JP2010511025A JP5513375B2 (ja) 2008-05-07 2009-05-07 癌の検出方法および検出用キット、ならびに癌治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014064000A Division JP5867757B2 (ja) 2008-05-07 2014-03-26 癌の検出方法および検出用キット、ならびに癌治療剤

Publications (2)

Publication Number Publication Date
JPWO2009136501A1 JPWO2009136501A1 (ja) 2011-09-08
JP5513375B2 true JP5513375B2 (ja) 2014-06-04

Family

ID=41264558

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010511025A Active JP5513375B2 (ja) 2008-05-07 2009-05-07 癌の検出方法および検出用キット、ならびに癌治療剤
JP2014064000A Expired - Fee Related JP5867757B2 (ja) 2008-05-07 2014-03-26 癌の検出方法および検出用キット、ならびに癌治療剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014064000A Expired - Fee Related JP5867757B2 (ja) 2008-05-07 2014-03-26 癌の検出方法および検出用キット、ならびに癌治療剤

Country Status (4)

Country Link
US (2) US8841268B2 (fr)
EP (1) EP2295598A4 (fr)
JP (2) JP5513375B2 (fr)
WO (1) WO2009136501A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE201100037A (et) 2011-05-16 2012-12-17 Tartu Ülikool MikroRNAde kasutamine biomarkeritena ja sihtm„rkidena raku proliferatiivsete omaduste m?jutamiseks ja meetod ning komplekt nende ekspressioonitaseme tuvastamiseks
KR20140057356A (ko) * 2011-08-31 2014-05-12 제넨테크, 인크. 진단 마커
WO2014126233A1 (fr) * 2013-02-15 2014-08-21 国立大学法人東京医科歯科大学 Procédé pour l'analyse de micro-arn, agent thérapeutique anticancéreux, et composition médicinale le contenant pour une thérapie anticancéreuse
WO2014151551A1 (fr) * 2013-03-15 2014-09-25 Baylor Research Institute Marqueurs d'une néoplasie colorectale associée à la colite ulcéreuse (uc)
JP2016201999A (ja) * 2013-08-26 2016-12-08 北海道公立大学法人 札幌医科大学 大腸癌を検出する方法
JP2016192909A (ja) * 2015-03-31 2016-11-17 シスメックス株式会社 胃癌に関する情報の取得方法、ならびに胃癌に関する情報を取得するためのマーカーおよび胃癌検出用キット
WO2018008153A1 (fr) * 2016-07-08 2018-01-11 有限会社ハヌマット Procédé de détermination de la possibilité de début d'un cancer du côlon
JP7094881B2 (ja) * 2016-07-08 2022-07-04 有限会社ハヌマット 大腸癌発症可能性の判定方法
CN108913777B (zh) * 2018-08-16 2022-10-18 上海市公共卫生临床中心 诊断肿瘤的dna甲基化相关的标记物及其应用
JP7398712B2 (ja) 2018-09-13 2023-12-15 国立研究開発法人国立がん研究センター 乳癌細胞存在率の推定方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6805869B2 (en) * 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
EP2290071B1 (fr) * 2004-05-28 2014-12-31 Asuragen, Inc. Procédés et compositions impliquant du microARN
ATE438740T1 (de) * 2004-12-02 2009-08-15 Epigenomics Ag Verfahren und nukleinsäuren zur analyse von mit der prognose von störungen der proliferation von prostatazellen assoziierter genexpression
EP2152722B1 (fr) * 2007-05-03 2016-04-27 Merck Sharp & Dohme Corp. Compositions comportant des agents therapeutiques mir34 pour traiter le cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6009025228; ＧＲＡＤＹ，　ＷＭ．，　ｅｔ　ａｌ．，: 'Ｅｐｉｇｅｎｅｔｉｃ　ｓｉｌｅｎｃｉｎｇ　ｏｆ　ｔｈｅ　ｉｎｔｒｏｎｉｃ　ｍｉｃｒｏＲＮＡ　ｈｓａ-ｍｉＲ-３４２　ａｎｄ　ｉｔｓ　ｈｏｓｔ　ｇｅｎｅ　ＥＶＬ　ｉｎ　ｃｏｌｏｒｅｃｔａｌ　ｃａｎｃｅｒ' Ｏｎｃｏｇｅｎｅ，　２００８　（ｐｕｂｌｉｓｈｅｄ　ｏｎｌｉｎｅ：　Ｆｅｂｒｕａｒｙ　１１，　２００８），　Ｖｏｌ．２７，　ｐｐ．３８８０-３８８８ *
JPN6009025236; ＣＯＲＮＥＹ，　ＤＣ．，　ｅｔ　ａｌ．: 'ＭｉｃｒｏＲＮＡ-３４ｂ　ａｎｄ　ＭｉｃｒｏＲＮＡ-３４ｃ　Ａｒｅ　Ｔａｒｇｅｔｓ　ｏｆ　ｐ５３　ａｎｄ　Ｃｏｏｐｅｒａｔｅ　ｉｎ　Ｃｏｎｔｒｏｌ　ｏｆ　Ｃｅｌｌ　Ｐｒｏｌｉｆｅｒａｔｉｏｎ　ａｎｄ' Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ，　２００７，　Ｖｏｌ．６７，　Ｎｏ．１８，　ｐｐ．８４３３-８４３８ *
JPN6009025238; ＬＵＪＡＭＢＩＯ，　Ａ．，　ｅｔ　ａｌ．，: 'ＣｐＧ　Ｉｓｌａｎｄ　Ｈｙｐｅｒｍｅｔｈｙｌａｔｉｏｎ　ｏｆ　Ｔｕｍｏｒ　Ｓｕｐｐｒｅｓｓｏｒ　ｍｉｃｒｏＲＮＡｓ　ｉｎ　Ｈｕｍａｎ　Ｃａｎｃｅｒ．' Ｃｅｌｌ　Ｃｙｃｌｅ，　２００７，　Ｖｏｌ．６，　Ｎｏ．１２，　ｐｐ．１４５５-１４５９ *
JPN6009025349; ＬＥＨＭＡＮＮ，　Ｕ．，　ｅｔ　ａｌ．，: 'Ｅｐｉｇｅｎｅｔｉｃ　ｉｎａｃｔｉｖａｔｉｏｎ　ｏｆ　ｍｉｃｒｏＲＮＡ　ｇｅｎｅ　ｈｓａ-ｍｉｒ-９-１　ｉｎ　ｈｕｍａｎ　ｂｒｅａｓｔ　ｃａｎｃｅｒ．' Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｐａｔｈｏｌｏｇｙ，　２００８　（Ｐｕｂｌｉｓｈｅｄ　Ｏｎｌｉｎｅ：　Ｏｃｔｏｂｅｒ　１８，　２００７），　Ｖｏｌ．２１４，　ｐｐ．１７-２４ *
JPN6009025352; ＡＵＥＲ，　ＲＬ．，　ｅｔ　ａｌ．，: 'Ｉｄｅｎｔｉｆｉｃａｔｉｏｎ　ｏｆ　ａ　ｐｏｔｅｎｔｉａｌ　ｒｏｌｅ　ｆｏｒ　ＰＯＵ２ＡＦ１　ａｎｄ　ＢＴＧ４　ｉｎ　ｔｈｅ　ｄｅｌｅｔｉｏｎ　ｏｆ　１１ｑ２３　ｉｎ　ｃｈｒｏｎｉｃ　ｌｙｍｐｈｏｃｙ' Ｇｅｎｅｓ，　Ｃｈｒｏｍｏｓｏｍｅｓ　ａｎｄ　Ｃａｎｃｅｒ，　２００５，　Ｖｏｌ．４３，　ｐｐ．１-１０ *
JPN6013057359; 'Ｃｅｌｌ　Ｃｙｃｌｅ' ２００７，　Ｖｏｌ．６，　Ｎｏ．９，　ｐｐ．１００１-１００５ *
JPN6013057362; 'Ｎａｔｕｒｅ　Ｇｅｎｅｔｉｃｓ' １９９６，　Ｖｏｌ．１４，　ｐｐ．４８２-４８６ *

Also Published As

Publication number Publication date
US20150031033A1 (en) 2015-01-29
JP5867757B2 (ja) 2016-02-24
US20110130341A1 (en) 2011-06-02
JP2014140377A (ja) 2014-08-07
JPWO2009136501A1 (ja) 2011-09-08
US8841268B2 (en) 2014-09-23
EP2295598A1 (fr) 2011-03-16
EP2295598A4 (fr) 2013-06-12
WO2009136501A1 (fr) 2009-11-12

Similar Documents

Publication Publication Date Title
JP5867757B2 (ja) 癌の検出方法および検出用キット、ならびに癌治療剤
Zhuo et al. Long noncoding RNA GMAN, up-regulated in gastric cancer tissues, is associated with metastasis in patients and promotes translation of ephrin A1 by competitively binding GMAN-AS
Gao et al. miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma
CN111961725B (zh) 胰腺癌的检测试剂盒或装置以及检测方法
Wei et al. Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma
de Souza Rocha Simonini et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor α in breast cancer cells
Kim et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR‐125a‐5p and MiR‐125b
Huang et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis
Desjobert et al. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression
Xie et al. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression
Ebrahimi et al. Deregulation of miR-126 expression in colorectal cancer pathogenesis and its clinical significance
Wang et al. Negative regulation of lncRNA GAS5 by miR-196a inhibits esophageal squamous cell carcinoma growth
Shen et al. MicroRNA-339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1
JP2010510769A (ja) 食道癌の診断ならびに患者の生存の予後および改善のための方法および組成物
Liu et al. Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer
Kong et al. Recent advances in understanding FOXN3 in breast cancer, and other malignancies
JPWO2013038737A1 (ja) 膀胱癌細胞の検出方法、膀胱癌細胞の検出方法に用いるプライマー及び膀胱癌マーカ
Zulueta et al. Transcriptional control of the B3GALT5 gene by a retroviral promoter and methylation of distant regulatory elements
AU2011343954A1 (en) Melanoma treatments
JP2012090555A (ja) Ｒａｓｇｒｆ１の定量的メチル化測定を用いた発癌リスク予測
WO2014200065A1 (fr) Composition de diagnostic et/ou de traitement du cancer colorectal et utilisation associée
Zheng et al. miR-129b suppresses cell proliferation in the human lung cancer cell lines A549 and H1299
JP5812491B2 (ja) 腫瘍治療剤
Yang et al. DNMT3B regulates proliferation of A549 cells through the microRNA‑152‑3p/NCAM1 pathway
US20220389420A1 (en) Agents for the treatment of patients with nsclc and methods to predict response

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120507

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130930

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20131018

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20131106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131126

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20140107

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140107

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140327

R150 Certificate of patent or registration of utility model

Ref document number: 5513375

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD14 Notification of resignation of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D14

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250